Oncologix Tech Stock Number Of Shares Shorted
| OCLG Stock | USD 0.0001 0.00 0.00% |
Oncologix Tech fundamentals help investors to digest information that contributes to Oncologix Tech's financial success or failures. It also enables traders to predict the movement of Oncologix Pink Sheet. The fundamental analysis module provides a way to measure Oncologix Tech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncologix Tech pink sheet.
Oncologix |
Oncologix Tech Company Number Of Shares Shorted Analysis
Oncologix Tech's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Oncologix Tech has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Health Care Providers & Services sector and about the same as Health Care (which currently averages 0.0) industry. The number of shares shorted for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Oncologix Fundamentals
| Return On Asset | -0.12 | |||
| Profit Margin | (0.38) % | |||
| Operating Margin | (0.13) % | |||
| Current Valuation | 3.18 M | |||
| Shares Outstanding | 340.13 M | |||
| Price To Earning | (0.03) X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 2.85 M | |||
| Gross Profit | 614.41 K | |||
| EBITDA | (572.25 K) | |||
| Net Income | (2.37 M) | |||
| Cash And Equivalents | 86.31 K | |||
| Total Debt | 3.97 M | |||
| Current Ratio | 0.28 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (24.2 K) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 191 | |||
| Beta | 1.27 | |||
| Market Capitalization | 612.23 K | |||
| Total Asset | 1.5 M | |||
| Retained Earnings | (49.86 M) | |||
| Working Capital | (3.35 M) | |||
| Current Asset | 1.31 M | |||
| Current Liabilities | 4.67 M | |||
| Z Score | -47.6 | |||
| Net Asset | 1.5 M |
About Oncologix Tech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncologix Tech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncologix Tech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncologix Tech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Oncologix Pink Sheet
Oncologix Tech financial ratios help investors to determine whether Oncologix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncologix with respect to the benefits of owning Oncologix Tech security.